---
title: 'Efficacy and Safety of Empagliflozin According to Background Diuretic Use in Heart Failure
  With Reduced Ejection Fraction: Post-Hoc Analysis of EMPEROR-Reduced'
date: '2023-09-16'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37715769/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230917180952&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Empagliflozin exhibits a consistent effect on time to CV
  death or HF hospitalization and an unaltered safety profile regardless of baseline
  diuretic therapy. (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure
  With Reduced Ejection Fraction [EMPEROR-Reduced]; ...'
disable_comments: true
---
CONCLUSIONS: Empagliflozin exhibits a consistent effect on time to CV death or HF hospitalization and an unaltered safety profile regardless of baseline diuretic therapy. (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction [EMPEROR-Reduced]; ...